title: sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors.
abstract: OBJECTIVE
  Soluble P-selectin (sP-sel) represents a marker of platelet activation. This study was addressed to investigate the associations of sP-sel plasma levels with anthropometric parameters, insulin resistance, and related metabolic and prothrombotic factors.
  
  
  RESULTS
  50 non-diabetic women, 17 with normal weight and 33 overweight and obese, aged 18-55 years, were examined. Measurements included body mass index (BMI), central fat accumulation (evaluated by waist circumference), systolic and diastolic blood pressure levels, fasting plasma concentrations of sP-sel, glucose, lipids (triglycerides, total cholesterol and HDL-cholesterol), insulin, and prothrombotic factors (plasminogen activator inhibitor-1, von Willebrand factor, fibrinogen), and insulin resistance (estimated by the homeostasis model assessment: HOMA(IR)). Overweight and obese women had higher fasting plasma sP-sel concentrations compared to normal-weight controls (P<0.05). sP-sel concentrations were positively correlated with BMI, HOMA(IR), systolic and diastolic blood pressure, fasting insulin, triglyceride and PAI-1 plasma levels (P<0.05 for all the correlations). When a multiple regression analysis was performed, with P-sel as dependent variable and all the other parameters as independent variables, P-sel did not maintain a significant relationship with any of these variables.
  
  
  CONCLUSIONS
  s-P-selectin plasma concentrations are higher in overweight and obese insulin resistant subjects, thus possibly contributing to the cardiovascular risk of these patients. However, body fatness and insulin resistance are not independent determinants of fasting plasma sP-sel concentrations.
authors.affiliation: Internal Medicine, Endocrinology, and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari, School of Medicine, Piazza Giulio Cesare, 70124 Bari, Italy. g.depergola@endo.uniba.it
authors.forename: G
authors.initials: G
authors.lastname: De Pergola
authors.forename: N
authors.initials: N
authors.lastname: Pannacciulli
authors.forename: M
authors.initials: M
authors.lastname: Coviello
authors.forename: A
authors.initials: A
authors.lastname: Scarangella
authors.forename: P
authors.initials: P
authors.lastname: Di Roma
authors.forename: M
authors.initials: M
authors.lastname: Caringella
authors.forename: M T
authors.initials: MT
authors.lastname: Venneri
authors.forename: M
authors.initials: M
authors.lastname: Quaranta
authors.forename: R
authors.initials: R
authors.lastname: Giorgino
mesh_terms: D000293:Adolescent; D000328:Adult; D000886:Anthropometry; D001786:Blood Glucose / Q000378:metabolism*; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology; D016022:Case-Control Studies; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D019007:P-Selectin / Q000097:blood*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D015539:Platelet Activation; D012044:Regression Analysis; D012307:Risk Factors; D012995:Solubility; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D001786:Blood Glucose; D008055:Lipids; D019007:P-Selectin; D017395:Plasminogen Activator Inhibitor 1; D014841:von Willebrand Factor; D005340:Fibrinogen